Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BIIB 
Biogen Inc (BIIB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BIIB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -20.5% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 19.33B USD | Price to earnings Ratio 11.81 | 1Y Target Price 200.12 |
Price to earnings Ratio 11.81 | 1Y Target Price 200.12 | ||
Volume (30-day avg) 1730483 | Beta 0.01 | 52 Weeks Range 128.51 - 238.00 | Updated Date 04/1/2025 |
52 Weeks Range 128.51 - 238.00 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 11.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.87% | Operating Margin (TTM) 21.51% |
Management Effectiveness
Return on Assets (TTM) 5.29% | Return on Equity (TTM) 10.36% |
Valuation
Trailing PE 11.81 | Forward PE 8.8 | Enterprise Value 23667582976 | Price to Sales(TTM) 2.09 |
Enterprise Value 23667582976 | Price to Sales(TTM) 2.09 | ||
Enterprise Value to Revenue 2.53 | Enterprise Value to EBITDA 8.66 | Shares Outstanding 146375008 | Shares Floating 146004608 |
Shares Outstanding 146375008 | Shares Floating 146004608 | ||
Percent Insiders 0.21 | Percent Institutions 94.37 |
Analyst Ratings
Rating 3.91 | Target Price 231.77 | Buy 5 | Strong Buy 13 |
Buy 5 | Strong Buy 13 | ||
Hold 16 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Biogen Inc
Company Overview
History and Background
Biogen Inc. was founded in 1978 in Geneva, Switzerland, by several prominent biologists, including Nobel laureates Walter Gilbert and Phillip Sharp. Originally named Biogen N.V., the company went public in 1983 and quickly became a pioneer in biotechnology, focusing on therapies for neurological and autoimmune diseases. It has evolved through strategic partnerships, acquisitions, and a focus on innovative drug development.
Core Business Areas
- Neurology: Focuses on treatments for neurological diseases, including multiple sclerosis (MS), spinal muscular atrophy (SMA), and Alzheimer's disease.
- Biosimilars: Develops and commercializes biosimilar versions of existing biologic drugs to provide more affordable treatment options.
- Rare Diseases: Developing new treatments to address unmet needs in rare diseases.
Leadership and Structure
The leadership team includes the CEO, Priya Singhal, MD. The company has a board of directors overseeing its strategic direction. The organizational structure is divided into research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Spinraza: A treatment for spinal muscular atrophy (SMA). Competitors include Novartis' Zolgensma and Roche's Evrysdi. Revenue for 2023 was $1.68 billion. Global market share of SMA treatment is around 40%.
- Tysabri: A treatment for multiple sclerosis (MS). Competitors include Roche's Ocrevus and Novartis' Gilenya. Tysabri revenue for 2023 was $1.69 billion. This represents about 10% market share.
- Aduhelm: An antibody for the treatment of Alzheimer's disease. The drug's efficacy has been controversial, leading to limited market adoption. Competitors include Eisai's and Biogen's Leqembi (lecanemab).
- Tecfidera: A treatment for multiple sclerosis (MS), an oral fumarate therapy. Several generic products entered the market after patent expiry. Sales have drastically declined in recent years. Competitors include Novartis' Gilenya, Roche's Ocrevus, and generic versions of Tecfidera.
- Leqembi: A treatment for early Alzheimer's disease, developed in partnership with Eisai. Market adoption is gradually increasing. Competitors include Eli Lilly's donanemab.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense competition, rapid technological advancements, and high regulatory hurdles. Key trends include personalized medicine, gene therapy, and the development of biosimilars.
Positioning
Biogen is a leading biotechnology company with a strong focus on neurological disorders. It has a reputation for innovation and a robust pipeline of potential new therapies.
Total Addressable Market (TAM)
The total addressable market for neurological disease treatments is projected to reach hundreds of billions of dollars. Biogen is well-positioned to capture a significant share of this market through its existing portfolio and pipeline.
Upturn SWOT Analysis
Strengths
- Strong research and development capabilities
- Established presence in the neurology market
- Partnerships with leading research institutions
- Diverse product portfolio
- Expertise in biologics development
Weaknesses
- Reliance on a few key products
- Exposure to generic competition
- Controversies surrounding some products
- High research and development costs
- Patent expirations
Opportunities
- Expanding into new therapeutic areas
- Developing innovative gene therapies
- Leveraging biosimilar expertise
- Strategic acquisitions to expand pipeline
- Partnerships with emerging biotechnology companies
Threats
- Increasing competition from other biotechnology companies
- Regulatory challenges
- Pricing pressures
- Clinical trial failures
- Changes in healthcare policies
Competitors and Market Share
Key Competitors
- Roche (ROG.SW)
- Novartis (NOVN.SW)
- Eli Lilly (LLY)
Competitive Landscape
Biogen faces intense competition, especially in the MS market. Leqembi offers a potential advantage in Alzheimer's disease. Roche and Novartis are diversified pharmaceutical companies with broader portfolios.
Major Acquisitions
Reata Pharmaceuticals
- Year: 2023
- Acquisition Price (USD millions): 7300
- Strategic Rationale: Acquisition of Reata brings Skyclarys, a first-in-class therapy for Friedreich's ataxia (FA), a rare neurodegenerative disorder, expanding Biogen's rare disease portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been impacted by generic competition and the performance of new product launches.
Future Projections: Analysts project moderate revenue growth driven by Leqembi and other pipeline products.
Recent Initiatives: Focus on Alzheimer's disease with Leqembi and pipeline expansion in neurological disorders.
Summary
Biogen is a leading biotechnology company with a strong legacy in neurology. While facing challenges from generic competition and controversies surrounding some of its products, the company is strategically focused on expanding its pipeline and diversifying its portfolio, particularly in Alzheimer's disease with Leqembi. The acquisition of Reata Pharmaceuticals expands Biogen's rare disease portfolio. The company needs to successfully commercialize Leqembi and manage its patent expirations to achieve sustained growth.
Similar Companies
AMGN
Amgen Inc
AMGN
Amgen Inc
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
REGN
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biogen Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 1991-09-16 | President, CEO & Director Mr. Christopher A. Viehbacher | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 7605 | Website https://www.biogen.com |
Full time employees 7605 | Website https://www.biogen.com | ||
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.